Scientists test 'Living Drug' to heal scarred hearts
NCT ID NCT06902896
Summary
This early-stage study is testing a new cell therapy for people with severe, end-stage heart failure from dilated cardiomyopathy. Researchers are modifying a patient's own immune cells to target and reduce scarring in the heart muscle, with the goal of improving heart function. The main focus is to check if this treatment is safe for a small group of 9 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Second Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, Zhejiang, 310009, China
Conditions
Explore the condition pages connected to this study.